ArticleScientific reports2025
Deep learning for automatic segmentation of hepatocellular carcinoma in contrast enhanced CT scans.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- DTARNU-Net: Dense Tiered Attention Residual Nested U-Net for CT Liver Tumor Segmentation.Bioengineering (Basel, Switzerland) · 2026Article
- Deep learning-based auto-segmentation and RECIST evaluation after concurrent chemoradiotherapy in locally advanced hepatocellular carcinoma patients.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Liver cancer represents a significant cause of cancer-related mortality, with hepatocellular carcinoma (HCC) being the most prevalent forms. Computed tomography (CT) serves as the principal imaging modality for the diagnosis of liver tumors, particularly HCC. The precise identification of tumor presence and location necessitates highly skilled radiologists. Consequently, automated liver tumor segmentation from CT images offers a valuable tool to support cancer diagnosis and treatment planning. Nevertheless, this task presents considerable challenges due to the inherent variability in tumor shape, dimension, and imaging acquisition techniques. In this paper, we evaluate state-of-the-art segmentation architectures across a range of datasets. These include the publicly accessible Liver Tumor Segmentation (LiTS) dataset, which covers a spectrum of liver lesions, as well as the HCC-TACE-Seg and WAW-TACE datasets, comprising CT scans of HCC patients prior to treatment. In addition, we introduce a novel dataset of contrast-enhanced CT (CECT) scans that are routinely used for HCC diagnosis. The focus of this manuscript is on the segmentation of both the liver and tumors, with specific attention directed toward HCC. This study provides a comparative analysis of segmentation models applied to diverse datasets, encompassing both public and proprietary datasets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.